The Clinical Kinase Index: Prioritizing Understudied Kinases at Targets…

Abstract  The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment-the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Read more “The Clinical Kinase Index: Prioritizing Understudied Kinases at Targets for the Treatment of Cancer” →